Apricoxib: Difference between revisions
Content deleted Content added
→See also: typo |
Remove malformatted |molecular_weight= when infobox can autocalculate it, per Wikipedia talk:WikiProject Pharmacology#Molecular weights in drugboxes (via WP:JWB) |
||
| Line 19: | Line 19: | ||
<!--Chemical data--> |
<!--Chemical data--> |
||
| C=19 | H=20 | N=2 | O=3 | S=1 |
| C=19 | H=20 | N=2 | O=3 | S=1 |
||
| molecular_weight = 356.4387 g/mol |
|||
| smiles = CCOC1=CC=C(C=C1)C2=CC(=CN2C3=CC=C(C=C3)S(=O)(=O)N)C |
| smiles = CCOC1=CC=C(C=C1)C2=CC(=CN2C3=CC=C(C=C3)S(=O)(=O)N)C |
||
| StdInChI = 1S/C19H20N2O3S/c1-3-24-17-8-4-15(5-9-17)19-12-14(2)13-21(19)16-6-10-18(11-7-16)25(20,22)23/h4-13H,3H2,1-2H3,(H2,20,22,23) |
| StdInChI = 1S/C19H20N2O3S/c1-3-24-17-8-4-15(5-9-17)19-12-14(2)13-21(19)16-6-10-18(11-7-16)25(20,22)23/h4-13H,3H2,1-2H3,(H2,20,22,23) |
||
Revision as of 03:34, 21 June 2020
 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C19H20N2O3S |
| Molar mass | 356.44 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Apricoxib is an experimental anticancer drug. It is a COX-2 inhibitor which is intended to improve standard therapy response in molecularly defined models of pancreatic cancer.[1] Development was abandoned in 2015 due to poor clinical trial results.[2]
See also
References
- ^ Kirane A, Toombs JE, Ostapoff K, Carbon JG, Zaknoen S, Braunfeld J, et al. (September 2012). "Apricoxib, a novel inhibitor of COX-2, markedly improves standard therapy response in molecularly defined models of pancreatic cancer". Clinical Cancer Research. 18 (18): 5031–42. doi:10.1158/1078-0432.CCR-12-0453. PMC 3777527. PMID 22829202.
- ^ "Apricoxib". Adis Insight. Springer Nature Switzerland AG.
 | This drug article relating to the musculoskeletal system is a stub. You can help Wikipedia by expanding it. |